Clinical practice of UroVysion® urine test in patients with bladder carcinoma in situ treated with intravesical Bacillus Calmette-Guerin

被引:1
作者
Miyake, Makito [1 ,4 ]
Hori, Shunta [1 ]
Fujii, Tomomi [2 ]
Nishimura, Nobutaka [1 ]
Oda, Yuki [1 ]
Miyamoto, Tatsuki [1 ]
Tomizawa, Mitsuru [1 ]
Shimizu, Takuto [1 ]
Ohnishi, Kenta [1 ]
Morizawa, Yosuke [1 ]
Gotoh, Daisuke [1 ]
Nakai, Yasushi [1 ]
Torimoto, Kazumasa [1 ]
Tanaka, Nobumichi [1 ,3 ]
Fujimoto, Kiyohide [1 ]
机构
[1] Nara Med Univ, Dept Urol, Kashihara, Japan
[2] NaraMed Univ, Dept Diagnost Pathol, Kashihara, Japan
[3] Nara Med Univ, Dept Prostate Brachytherapy, Kashihara, Japan
[4] Nara Med Univ, Dept Urol, 840 Shijo Cho, Nara 6348522, Japan
关键词
bladder cancer; carcinoma in situ; Bacillus Calmette-Guerin; cytology; FISH; DIAGNOSIS;
D O I
10.1093/jjco/hyad029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In January 2019, the use of the UroVysion (R) urine test for surveillance of non-muscle invasive bladder cancer with carcinoma in situ (CIS) was approved in Japan. Clinical evidence of its use remains limited. Herein, we report the real-world clinical practice of the UroVysion test. Of 29 patients underwent at least one UroVysion test at our hospital from 2019 to 2022, only two (6.9%) tested positive without any visible tumor on the cystoscopy after the initial transurethral resection: a 77-year-old man with T1 high-grade tumor and concomitant CIS and a 76-year-old woman with CIS. The remaining 27 patients (93.1%) tested negative post-transurethral resection. This study was the first to report the Japanese real-world practice of the UroVysion test, demonstrating relatively low positive rate as compared to the previous reports from other countries. Further clinical evidence from other Japanese institutes needs to be accumulated to update the true value of this test.
引用
收藏
页码:629 / 632
页数:4
相关论文
共 13 条
[1]   European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) [J].
Babjuk, Marko ;
Burger, Maximilian ;
Capoun, Otakar ;
Cohen, Daniel ;
Comperat, Eva M. ;
Escrig, Jose L. Dominguez ;
Gontero, Paolo ;
Liedberg, Fredrik ;
Masson-Lecomte, Alexandra ;
Mostafid, A. Hugh ;
Palou, Joan ;
van Rhijn, Bas W. G. ;
Roupret, Morgan ;
Shariat, Shahrokh F. ;
Seisen, Thomas ;
Soukup, Viktor ;
Sylvester, Richard J. .
EUROPEAN UROLOGY, 2022, 81 (01) :75-94
[2]   The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guerin therapy for bladder cancer A diagnostic meta-analysis and systematic review [J].
Bao, Yige ;
Tu, Xiang ;
Chang, Tiancong ;
Qiu, Shi ;
Yang, Lu ;
Geng, Jiwen ;
Quan, Liuliu ;
Wei, Qiang .
MEDICINE, 2018, 97 (36)
[3]   Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline [J].
Chang, Sam S. ;
Boorjian, Stephen A. ;
Chou, Roger ;
Clark, Peter E. ;
Daneshmand, Siamak ;
Konety, Badrinath R. ;
Pruthi, Raj ;
Quale, Diane Z. ;
Ritch, Chad R. ;
Seigne, John D. ;
Skinner, Eila Curlee ;
Smith, Norm D. ;
McKiernan, James M. .
JOURNAL OF UROLOGY, 2016, 196 (04) :1021-1029
[4]   Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan [J].
Ikeda, Atsushi ;
Kojima, Takahiro ;
Kawai, Koji ;
Hinotsu, Shiro ;
Keino, Naoto ;
Shiga, Kenichiro ;
Miyake, Hideaki ;
Miyata, Yasuyoshi ;
Enomoto, Yutaka ;
Shimizu, Fumitaka ;
Anai, Satoshi ;
Matsuyama, Hideyasu ;
Suzuki, Chieko ;
Kanimoto, Yusuke ;
Shigeta, Keisuke ;
Naito, Seiji ;
Akaza, Hideyuki ;
Nishiyama, Hiroyuki .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (06) :1163-1169
[5]   Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guerin Therapy for Bladder Cancer: Results of a Prospective Trial [J].
Kamat, Ashish M. ;
Dickstein, Rian J. ;
Messetti, Fabrizio ;
Anderson, Roosevelt ;
Pretzsch, Shanna M. ;
Gonzalez, Graciela Noguera ;
Katz, Ruth L. ;
Khanna, Abha ;
Zaidi, Tanweer ;
Wu, Xifeng ;
Grossman, H. Barton ;
Dinney, Colin P. .
JOURNAL OF UROLOGY, 2012, 187 (03) :862-867
[6]   Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan [J].
Kojima, Takahiro ;
Nishiyama, Hiroyuki ;
Ozono, Seiichiro ;
Hinotsu, Shiro ;
Keino, Naoto ;
Yamaguchi, Akito ;
Sakai, Hideki ;
Enomoto, Yutaka ;
Horie, Shigeo ;
Fujimoto, Kiyohide ;
Matsuyama, Hideyasu ;
Okamura, Takehiko ;
Kanimoto, Yusuke ;
Oya, Mototsugu ;
Nonomura, Norio ;
Naito, Seiji ;
Akaza, Hideyuki .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (06) :1140-1147
[7]   Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper [J].
Matsumoto, Hiroaki ;
Shiraishi, Koji ;
Azuma, Haruhito ;
Inoue, Keiji ;
Uemura, Hirotsugu ;
Eto, Masatoshi ;
Ohyama, Chikara ;
Ogawa, Osamu ;
Kikuchi, Eiji ;
Kitamura, Hiroshi ;
Shinohara, Nobuo ;
Takahashi, Satoru ;
Tsuzuki, Toyonori ;
Nakagawa, Masayuki ;
Narumi, Yoshifumi ;
Nishiyama, Hiroyuki ;
Habuchi, Tomonori ;
Hinotsu, Shiro ;
Fujii, Yasuhisa ;
Fujimoto, Kiyohide ;
Fujimoto, Hiroyuki ;
Mizowaki, Takashi ;
Matsuyama, Hideyasu .
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (05) :362-368
[8]  
Miyake M, 2019, J CLIN PATHOL, V65, P140
[9]   Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma [J].
Miyake, Makito ;
Owari, Takuya ;
Hori, Shunta ;
Nakai, Yasushi ;
Fujimoto, Kiyohide .
RESEARCH AND REPORTS IN UROLOGY, 2018, 10 :251-261
[10]   UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives [J].
Nagai, Takashi ;
Naiki, Taku ;
Etani, Toshiki ;
Iida, Keitaro ;
Noda, Yusuke ;
Shimizu, Nobuhiko ;
Isobe, Teruki ;
Nozaki, Satoshi ;
Okamura, Takehiko ;
Ando, Ryosuke ;
Kawai, Noriyasu ;
Yasui, Takahiro .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (04) :1-10